Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?

Journal of Clinical Lipidology

Volumn 9, Issue 4, 2015, Pages 568-575

  Othman, Alaa ^a,b,c   Benghozi, Renee ^d   Alecu, Irina ^a,b   Wei, Yu ^a   Niesor, Eric ^d   Von Eckardstein, Arnold ^a,b   Hornemann, Thorsten ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF LÜBECK   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

1 deoxysphingolipids; Alanine; Diabetic neuropathy; Fenofibrate; MetS; Niacin; Serine; Serine Palmitoyltransferase; sphingolipids; T2DM

Indexed keywords

1 DEOXY SPHINGOLIPID; ACYL COENZYME A; ALANINE; FENOFIBRATE; GLYCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PALMITOYL COENZYME A; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES; MALE; MUTATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

SPHINGOIDEA;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; FENOFIBRATE; HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NIACIN; SPHINGOLIPIDS; TRIGLYCERIDES;

EID: 84938197335     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.03.011     Document Type: Article

References (41)

1. Z. Reiner, A.L. Catapano, G. De Backer, and et al. ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 32 2011 1769 1818
2. J.D. Brunzell, M. Davidson, C.D. Furberg, and et al. Lipoprotein management in patients with cardiometabolic risk-consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
4. I. Issemann, and S. Green Activation of a member of the steroid-hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
5. D.J. Mangelsdorf, and R.M. Evans The Rxr heterodimers and orphan receptors Cell 83 1995 841 850
6. A. Schmidt, N. Endo, S.J. Rutledge, R. Vogel, D. Shinar, and G.A. Rodan Identification of a new member of the steroid-hormone receptor superfamily that is activated by a peroxisome proliferator and fatty-acids Mol Endocrinol 6 1992 1634 1641
7. T. Sher, H.F. Yi, O.W. Mcbride, and F.J. Gonzalez cDNA cloning, chromosomal mapping, and functional-characterization of the human peroxisome proliferator activated receptor Biochemistry 32 1993 5598 5604
8. K.G. Lambe, and J.D. Tugwood A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs Eur J Biochem 239 1996 1 7
9. K. McKeage, and G.M. Keating Fenofibrate: a review of its use in dyslipidaemia Drugs 71 2011 1917 1946
10. A. Wise, S.M. Foord, N.J. Fraser, and et al. Molecular identification of high and low affinity receptors for nicotinic acid J Biol Chem 278 2003 9869 9874
11. T. Soga, M. Kamohara, J. Takasaki, and et al. Molecular identification of nicotinic acid receptor Biochem Biophys Res Commun 303 2003 364 369
12. S. Tunaru, J. Kero, A. Schaub, and et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat Med 9 2003 352 355
13. J.W. van der Hoorn, W. de Haan, J.F. Berbee, and et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice Arterioscler Thromb Vasc Biol 28 2008 2016 2022
14. J.E. Digby, N. Ruparelia, and R.P. Choudhury Niacin in cardiovascular disease: recent preclinical and clinical developments Arterioscler Thromb Vasc Biol 32 2012 582 588
15. O. Quehenberger, A.M. Armando, A.H. Brown, and et al. Lipidomics reveals a remarkable diversity of lipids in human plasma J Lipid Res 51 2010 3299 3305
16. O. Quehenberger, and E.A. Dennis Mechanisms of disease: the human plasma lipidome N Engl J Med 365 2011 1812 1823
17. A. Othman, M.F. Rutti, D. Ernst, and et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 55 2012 421 431
18. H. Katsikas, and C. Wolf Blood sphingomyelins from two European countries Biochim Biophys Acta 1258 1995 95 100
19. M. Bertea, M.F. Rütti, A. Othman, and et al. Deoxysphingoid bases as plasma markers in diabetes mellitus Lipids Health Dis 9 2010 84
20. R.A. Zuellig, T. Hornemann, A. Othman, and et al. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells Diabetes 63 2014 1326 1339
21. A. Othman, R. Bianchi, I. Alecu, and et al. Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats Diabetes 64 2014 1035 1045
22. G. Franceschini, E. Favari, L. Calabresi, and et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients J Clin Lipidol 7 2013 414 422
23. E.J. Niesor, K. Gauthamadasa, R.A. Silva, and et al. Xanthophylls, phytosterols and pre-beta 1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study Lipids 48 2013 1185 1196
24. L.M. Obeid, Y. Okamoto, and C. Mao Yeast sphingolipids: metabolism and biology Biochim Biophys Acta 1585 2002 163 171
25. H.H. Bui, J.K. Leohr, and M.S. Kuo Analysis of sphingolipids in extracted human plasma using liquid chromatography electrospray ionization tandem mass spectrometry Anal Biochem 423 2012 187 194
26. D.L. Gorden, D.S. Myers, P.T. Ivanova, and et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic J Lipid Res 56 2015 722 736
27. A. Penno, M.M. Reilly, H. Houlden, and et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids J Biol Chem 285 2010 11178 11187
28. J.L. Dawkins, D.J. Hulme, S.B. Brahmbhatt, M. Auer-Grumbach, and G.A. Nicholson Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I Nat Genet 27 2001 309 312
29. A. Rotthier, M. Auer-Grumbach, K. Janssens, and et al. Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I Am J Hum Genet 87 2010 513 522
30. K. Garofalo, A. Penno, B.P. Schmidt, and et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1 J Clin Invest 121 2011 4735 4745
31. T.M.E. Davis, B.B. Yeap, W.A. Davis, and D.G. Bruce Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study Diabetologia 51 2008 562 566
32. G. Steiner How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD Cardiovasc Drugs Ther 23 2009 403 408
33. T. Hornemann, S. Richard, M.F. Rütti, Y. Wei, and A. v Eckardstein Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase J Biol Chem 281 2006 37275 37281
34. T. Hornemann, A. Penno, M.F. Rütti, and et al. The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases J Biol Chem 284 2009 26322 26330
35. G. Han, S.D. Gupta, K. Gable, and et al. Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities Proc Natl Acad Sci U S A 106 2009 8186 8191
36. P. Zabielski, A. Blachnio-Zabielska, M. Baranowski, M. Zendzian-Piotrowska, and J. Gorski Activation of PPARalpha by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver Prostaglandins Other Lipid Mediat 93 2010 120 125
37. P. Zabielski, M. Baranowski, M. Zendzian-Piotrowska, A. Blachnio-Zabielska, and J. Gorski Bezafibrate decreases growth stimulatory action of the sphingomyelin signaling pathway in regenerating rat liver Prostaglandins Other Lipid Mediat 85 2008 17 25
38. M. Baranowski, A. Blachnio, P. Zabielski, and J. Gorski Pioglitazone induces de novo ceramide synthesis in the rat heart Prostaglandins Other Lipid Mediat 83 2007 99 111
39. K. Tsuji, S. Satoh, S. Mitsutake, and et al. Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors Bioorg Med Chem Lett 19 2009 1643 1646
40. P.P. Van Veldhoven, G.P. Mannaerts, P. Declercq, and M. Baes Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)? Cell Signal 12 2000 475 479
41. I. Murakami, Y. Wakasa, S. Yamashita, and et al. Phytoceramide and sphingoid bases derived from brewer's yeast Saccharomyces pastorianus activate peroxisome proliferator-activated receptors Lipids Health Dis 10 2011 150